Author | Luca Gianni, MD

June 14, 2011

Dr. Gianni has been involved with new drug therapies in medical oncology for some time, and in this interview he discusses the changing use of breast cancer treatments, neoadjuvant regimens, and research and developments on HER2-positive breast cancer.

January 01, 1998

A pilot study conducted at the National Cancer Institute in Milan, Italy assessed the efficacy of six or eight cycles of paclitaxel (Taxol) 200 mg/m² q3wks plus doxorubicin (Adriamycin) (60 mg/m² q3wks) in 49 women with